Amarin | AMRN - Current Liabilities


Amarin reported $179.64M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
AbbVie USD 42.1B 1.19B Mar/2026
Alnylam Pharmaceuticals USD 1.35B 116.87M Mar/2026
Amarin USD 179.64M 14.82M Mar/2026
AstraZeneca USD 32.57B 1.95B Mar/2026
BioCryst Pharmaceuticals USD 195.39M 675K Mar/2026
DBV Technologies USD 58.02M 8.54M Dec/2025
Esperion Therapeutics USD 300.36M 451K Mar/2026
GlaxoSmithKline GBP 22.43B 1.04B Mar/2026
Halozyme Therapeutics USD 363.21M 186.12M Mar/2026
Heron Therapeutics USD 90.52M 5.58M Mar/2026
Ionis Pharmaceuticals USD 717M 66M Mar/2026
Nektar Therapeutics USD 53.54M 12.8M Dec/2025
Neurocrine Biosciences USD 831.7M 88.3M Mar/2026
Novartis USD 31.37B 4.1B Mar/2026